TY - JOUR
T1 - Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis
AU - Marrie, Ruth Ann
AU - Leung, Stella
AU - Cutter, Gary R.
AU - Fox, Robert J.
AU - Salter, Amber
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.A.M. is the journal co-editor for Multiple Sclerosis Journal: Experimental, Translational and Clinical; received research funding from CIHR, MS Society of Canada, MS Scientific Research Foundation, National MS Society, Crohn’s and Colitis Canada, the US Department of Defense, The Arthritis Society, the CMSC; and was supported by the Waugh Family Chair in Multiple Sclerosis. S.L. has nothing to disclose. G.C. is in data/safety monitoring committees for AMO, BioLineRx, BrainStorm Cell Therapeutics, Galmed, Horizon, Hisun, Merck, Merck/Pfizer, OPKO Biologics, Neurim, Novartis, Orphazyme, Sanofi, Reata, Receptos/Celgene, Teva, NHLBI (Protocol Review Committee), and NICHD (OPRU oversight committee) and consulting/advisory boards for Biogen, Click Therapeutics, Genzyme, Genentech, GW, Klein Buendel, MedImmune, MedDay, Novartis, Osmotica, Perception Neuroscience, Recursion, Roche, Somahlution, and TG Therapeutics. R.J.F. received consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva; is in advisory committees for Actelion, Biogen, Immunic, and Novartis; received research grant funding from Novartis. A.S. is the journal editor/member of editorial advisory board for Circulation: Cardiovascular Imaging.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NARCOMS is funded in part by the CMSC and the Foundation of the CMSC. The study was also supported in part by the Waugh Family Chair in Multiple Sclerosis and Research Manitoba Chair (to R.A.M.). The funding source(s) had no role in the study design, collection, analysis, or interpretation of the data, nor in the decision to submit the article for publication.
Publisher Copyright:
© The Author(s), 2021.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Outcome measures need to be valid and have good test–retest reliability and responsiveness. We compared the responsiveness of the RAND-12 and the Health Utilities Index—mark III (HUI3) in persons with multiple sclerosis (MS). Methods: In Spring 2018 and 2019, North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants completed the HUI3, the RAND-12, and reported disability (Patient Determined Disease Steps (PDDS)) and employment status (full-time, part-time, and no). We used changes in PDDS and employment status as anchors. We assessed responsiveness using effect size, standardized response mean, and the responsiveness index. We used relative efficiency (RE) to compare the responsiveness of the health-related quality of life (HRQOL) scores, adjusting for sociodemographic factors. Results: We included 4769 participants in the analysis. They had a mean (standard deviation (SD)) age of 60.9 (10.1) years, and 3826 participants (80.2%) were women. RE was highest for the HUI3 for changes in in disability status (HUI3: 1.0, Physical Component Score-12 (PCS-12): 0.80, and Mental Component Score-12 (MCS-12): 0.41) and for changes in employment status (HUI3: 1.0, PCS-12: 0.70, and MCS-12: 0.17). Conclusion: The HUI3 was more responsive to changes in disability and employment status than the PCS-12 or MCS-12. Given the HUI3’s other strong psychometric properties, it may be the preferred generic measure of HRQOL in MS.
AB - Background: Outcome measures need to be valid and have good test–retest reliability and responsiveness. We compared the responsiveness of the RAND-12 and the Health Utilities Index—mark III (HUI3) in persons with multiple sclerosis (MS). Methods: In Spring 2018 and 2019, North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants completed the HUI3, the RAND-12, and reported disability (Patient Determined Disease Steps (PDDS)) and employment status (full-time, part-time, and no). We used changes in PDDS and employment status as anchors. We assessed responsiveness using effect size, standardized response mean, and the responsiveness index. We used relative efficiency (RE) to compare the responsiveness of the health-related quality of life (HRQOL) scores, adjusting for sociodemographic factors. Results: We included 4769 participants in the analysis. They had a mean (standard deviation (SD)) age of 60.9 (10.1) years, and 3826 participants (80.2%) were women. RE was highest for the HUI3 for changes in in disability status (HUI3: 1.0, Physical Component Score-12 (PCS-12): 0.80, and Mental Component Score-12 (MCS-12): 0.41) and for changes in employment status (HUI3: 1.0, PCS-12: 0.70, and MCS-12: 0.17). Conclusion: The HUI3 was more responsive to changes in disability and employment status than the PCS-12 or MCS-12. Given the HUI3’s other strong psychometric properties, it may be the preferred generic measure of HRQOL in MS.
KW - Multiple sclerosis
KW - quality of life
KW - responsiveness
UR - http://www.scopus.com/inward/record.url?scp=85098981321&partnerID=8YFLogxK
U2 - 10.1177/1352458520981370
DO - 10.1177/1352458520981370
M3 - Article
C2 - 33399503
AN - SCOPUS:85098981321
SN - 1352-4585
VL - 27
SP - 1781
EP - 1789
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 11
ER -